Neuroprotection for glaucoma: Requirements for clinical translation

Experimental Eye Research

Volumn 157, Issue , 2017, Pages 34-37

  Levin, Leonard A ^c,d   Crowe, Megan E ^d   Quigley, Harry A ^e   Cordeiro, M Francesca ^a   Donoso, Larry A ^b   Liao, Y Joyce ^b   Libby, Richard T ^b   Masland, Richard H ^b   Nickells, Robert W ^b   Sieving, Paul A ^b   Sommer, Alfred ^b  

^a London   (United Kingdom)

^b University of Wisconsin School of Medicine and Public Health ^*  (United States)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Astrocytes; Axons; Glaucoma; Neuroprotection; Retinal ganglion cells

Indexed keywords

NEUROPROTECTIVE AGENT; NEW DRUG;

ANATOMICAL CONCEPTS; ANIMAL MODEL; ARTICLE; BIOCHEMICAL COMPOSITION; DRUG EFFICACY; DRUG TARGETING; FUTUROLOGY; GLAUCOMA; HUMAN; MULTICENTER STUDY (TOPIC); NEUROPROTECTION; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ANIMAL; ASTROCYTE; AXON; DRUG EFFECTS; OPTIC NERVE DISEASES; PHYSIOLOGY; RETINA GANGLION CELL; TRANSLATIONAL RESEARCH;

ANIMALS; ASTROCYTES; AXONS; GLAUCOMA; HUMANS; NEUROPROTECTION; NEUROPROTECTIVE AGENTS; OPTIC NERVE DISEASES; RETINAL GANGLION CELLS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 85009733749     PISSN: 00144835     EISSN: 10960007     Source Type: Journal    
DOI: 10.1016/j.exer.2016.12.005     Document Type: Article

References (46)

1. Almasieh, M., Lieven, C.J., Levin, L.A., Di Polo, A., A cell-permeable phosphine-borane complex delays retinal ganglion cell death after axonal injury through activation of the pro-survival extracellular signal-regulated kinases 1/2 pathway. J. Neurochem. 118 (2011), 1075–1086.
2. Almasieh, M., Wilson, A.M., Morquette, B., Cueva Vargas, J.L., Di Polo, A., The molecular basis of retinal ganglion cell death in glaucoma. Prog. Retin Eye Res. 31 (2012), 152–181.
3. Bai, Y., Dergham, P., Nedev, H., Xu, J., Galan, A., Rivera, J.C., ZhiHua, S., Mehta, H.M., Woo, S.B., Sarunic, M.V., Neet, K.E., Saragovi, H.U., Chronic and acute models of retinal neurodegeneration TrkA activity are neuroprotective whereas p75NTR activity is neurotoxic through a paracrine mechanism. J. Biol. Chem. 285 (2010), 39392–39400.
4. Chang, E.E., Goldberg, J.L., Glaucoma 2.0: neuroprotection, neuroregeneration, neuroenhancement. Ophthalmology 119 (2012), 979–986.
5. Chong, R.S., Martin, K.R., Glial cell interactions and glaucoma. Curr. Opin. Ophthalmol. 26:2 (2015), 73–77.
6. Cordeiro, M.F., Guo, L., Luong, V., Harding, G., Wang, W., Jones, H.E., Moss, S.E., Sillito, A.M., Fitzke, F.W., Real-time imaging of single nerve cell apoptosis in retinal neurodegeneration. Proc. Natl. Acad. Sci. U. S. A. 101 (2004), 13352–13356.
7. Dahlmann-Noor, A., Vijay, S., Jayaram, H., Limb, A., Khaw, P.T., Current approaches and future prospects for stem cell rescue and regeneration of the retina and optic nerve. Can. J. Ophthalmol. 45 (2010), 333–341.
8. Danesh-Meyer, H.V., Neuroprotection in glaucoma: recent and future directions. Curr. Opin. Ophthalmol. 22 (2011), 78–86.
9. Danesh-Meyer, H.V., Levin, L.A., Glaucoma as a neurodegenerative disease. J. Neuro-Ophthalmology 35 (2015), S22–S28.
10. Dunkel, P., Chai, C.L., Sperlagh, B., Huleatt, P.B., Matyus, P., Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis. Expert Opin. Investig. Drugs 21 (2012), 1267–1308.
11. Ergorul, C., Levin, L.A., Solving the lost in translation problem: improving the effectiveness of translational research. Curr. Opin. Pharmacol. 13 (2013), 108–114.
12. Garway-Heath, D.F., Crabb, D.P., Bunce, C., Lascaratos, G., Amalfitano, F., Anand, N., Azuara-Blanco, A., Bourne, R.R., Broadway, D.C., Cunliffe, I.A., Diamond, J.P., Fraser, S.G., Ho, T.A., Martin, K.R., McNaught, A.I., Negi, A., Patel, K., Russell, R.A., Shah, A., Spry, P.G., Suzuki, K., White, E.T., Wormald, R.P., Xing, W., Zeyen, T.G., Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet 385 (2015), 1295–1304.
13. Gupta, N., Greenberg, G., de Tilly, L.N., Gray, B., Polemidiotis, M., Yucel, Y.H., Atrophy of the lateral geniculate nucleus in human glaucoma detected by magnetic resonance imaging. Br. J. Ophthalmol. 93 (2009), 56–60.
14. Heijl, A., Leske, M.C., Bengtsson, B., Hyman, L., Hussein, M., Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch. Ophthalmol. 120 (2002), 1268–1279.
15. Howell, G.R., Libby, R.T., Jakobs, T.C., Smith, R.S., Phalan, F.C., Barter, J.W., Barbay, J.M., Marchant, J.K., Mahesh, N., Porciatti, V., Whitmore, A.V., Masland, R.H., John, S.W., Axons of retinal ganglion cells are insulted in the optic nerve early in DBA/2J glaucoma. J. Cell Biol. 179 (2007), 1523–1537.
16. Huntwork-Rodriguez, S., Wang, B., Watkins, T., Ghosh, A.S., Pozniak, C.D., Bustos, D., Newton, K., Kirkpatrick, D.S., Lewcock, J.W., JNK-mediated phosphorylation of DLK suppresses its ubiquitination to promote neuronal apoptosis. J. Cell Biol. 202 (2013), 747–763.
17. Ji, J.Z., Elyaman, W., Yip, H.K., Lee, V.W., Yick, L.W., Hugon, J., So, K.F., CNTF promotes survival of retinal ganglion cells after induction of ocular hypertension in rats: the possible involvement of STAT3 pathway. Eur. J. Neurosci. 19 (2004), 265–272.
18. Johnson, E.C., Morrison, J.C., Friend or foe? Resolving the impact of glial responses in glaucoma. J. Glaucoma 18 (2009), 341–353.
19. Johnson, T.V., Bull, N.D., Hunt, D.P., Marina, N., Tomarev, S.I., Martin, K.R., Neuroprotective effects of intravitreal mesenchymal stem cell transplantation in experimental glaucoma. Invest. Ophthalmol. Vis. Sci. 51 (2010), 2051–2059.
20. Kanamori, A., Catrinescu, M.M., Mahammed, A., Gross, Z., Levin, L.A., Neuroprotection against superoxide anion radical by metallocorroles in cellular and murine models of optic neuropathy. J. Neurochem. 114 (2010), 488–498.
21. Lee, D., Shim, M.S., Kim, K.Y., Noh, Y.H., Kim, H., Kim, S.Y., Weinreb, R.N., Ju, W.K., Coenzyme Q10 inhibits glutamate excitotoxicity and oxidative stress-mediated mitochondrial alteration in a mouse model of glaucoma. Invest. Ophthalmol. Vis. Sci. 55 (2014), 993–1005.
22. Levin, L.A., Relevance of the site of injury of glaucoma to neuroprotective strategies. Surv. Ophthalmol. 45 (2001), S243–S249.
23. Levin, L.A., Danesh-Meyer, H.V., Lost in translation: bumps in the road between bench and bedside. JAMA 303 (2010), 1533–1534.
24. Levin, L.A., Peeples, P., History of neuroprotection and rationale as a therapy for glaucoma. Am. J. Manag. Care 14 (2008), S11–S14.
25. Mansour-Robaey, S., Clarke, D.B., Wang, Y.C., Bray, G.M., Aguayo, A.J., Effects of ocular injury and administration of brain-derived neurotrophic factor on survival and regrowth of axotomized retinal ganglion cells. Proc. Natl. Acad. Sci. U. S. A. 91 (1994), 1632–1636.
26. Martin, K.R., Quigley, H.A., Zack, D.J., Levkovitch-Verbin, H., Kielczewski, J., Valenta, D., Baumrind, L., Pease, M.E., Klein, R.L., Hauswirth, W.W., Gene therapy with brain-derived neurotrophic factor as a protection: retinal ganglion cells in a rat glaucoma model. Invest. Ophthalmol. Vis. Sci. 44 (2003), 4357–4365.
27. McKean-Cowdin, R., Wang, Y., Wu, J., Azen, S.P., Varma, R., Impact of visual field loss on health-related quality of life in glaucoma: the Los Angeles Latino Eye Study. Ophthalmology 115 (2008), 941–948 e941.
28. Nguyen, C., Cone, F.E., Nguyen, T.D., Coudrillier, B., Pease, M.E., Steinhart, M.R., Oglesby, E.N., Jefferys, J.L., Quigley, H.A., Studies of scleral biomechanical behavior related to susceptibility for retinal ganglion cell loss in experimental mouse glaucoma. Invest. Ophthalmol. Vis. Sci. 54 (2013), 1767–1780.
29. Nickells, R.W., Howell, G.R., Soto, I., John, S.W., Under pressure: cellular and molecular responses during glaucoma, a common neurodegeneration with axonopathy. Annu. Rev. Neurosci. 35 (2012), 153–179.
30. Pelzel, H.R., Schlamp, C.L., Nickells, R.W., Histone H4 deacetylation plays a critical role in early gene silencing during neuronal apoptosis. BMC Neurosci., 11, 2010, 62.
31. Quigley, H.A., Clinical trials for glaucoma neuroprotection are not impossible. Curr. Opin. Ophthalmol. 23 (2012), 144–154.
32. Quigley, H.A., Addicks, E.M., Green, W.R., Maumenee, A.E., Optic nerve damage in human glaucoma. II. The site of injury and susceptibility to damage. Arch. Ophthalmol. 99 (1981), 635–649.
33. Quigley, H.A., Guy, J., Anderson, D.R., Blockade of rapid axonal transport. Effect of intraocular pressure elevation in primate optic nerve. Arch. Ophthalmol. 97 (1979), 525–531.
34. Quigley, H.A., Pitha, I.F., Welsbie, D.S., Nguyen, C., Steinhart, M.R., Nguyen, T.D., Pease, M.E., Oglesby, E.N., Berlinicke, C.A., Mitchell, K.L., Kim, J., Jefferys, J.J., Kimball, E.C., Losartan treatment protects retinal ganglion cells and alters scleral remodeling in experimental glaucoma. PLoS One, 10, 2015, e0141137.
35. Roddy, G., Ellemberg, D., Prevention of glaucoma through exercise: a meta-analysis. J. Vis., 12, 2012, 483.
36. Schmitt, H.M., Schlamp, C.L., Nickells, R.W., Role of HDACs in optic nerve damage-induced nuclear atrophy of retinal ganglion cells. Neurosci. Lett., 2015.
37. Son, J.L., Soto, I., Oglesby, E., Lopez-Roca, T., Pease, M.E., Quigley, H.A., Marsh-Armstrong, N., Glaucomatous optic nerve injury involves early astrocyte reactivity and late oligodendrocyte loss. Glia 58 (2010), 780–789.
38. Soto, I., Oglesby, E., Buckingham, B.P., Son, J.L., Roberson, E.D., Steele, M.R., Inman, D.M., Vetter, M.L., Horner, P.J., Marsh-Armstrong, N., Retinal ganglion cells downregulate gene expression and lose their axons within the optic nerve head in a mouse glaucoma model. J. Neurosci. 28 (2008), 548–561.
39. Uchibayashi, R., Tsuruma, K., Inokuchi, Y., Shimazawa, M., Hara, H., Involvement of Bid and caspase-2 in endoplasmic reticulum stress- and oxidative stress-induced retinal ganglion cell death. J. Neurosci. Res. 89 (2011), 1783–1794.
40. Wang, H., Wang, R., Thrimawithana, T., Little, P.J., Xu, J., Feng, Z.P., Zheng, W., The nerve growth factor signaling and its potential as therapeutic target for glaucoma. Biomed. Res. Int., 2014, 2014, 759473.
41. Weinreb, R.N., Kaufman, P.L., Glaucoma research community and FDA look to the future, II: NEI/FDA glaucoma clinical trial design and endpoints symposium: measures of structural change and visual function. Investigative Ophthalmol. Vis. Sci., 52, 2011, 7842.
42. Welsbie, D.S., Yang, Z., Ge, Y., Mitchell, K.L., Zhou, X., Martin, S.E., Berlinicke, C.A., Hackler, L. Jr., Fuller, J., Fu, J., Cao, L.H., Han, B., Auld, D., Xue, T., Hirai, S., Germain, L., Simard-Bisson, C., Blouin, R., Nguyen, J.V., Davis, C.H., Enke, R.A., Boye, S.L., Merbs, S.L., Marsh-Armstrong, N., Hauswirth, W.W., Diantonio, A., Nickells, R.W., Inglese, J., Hanes, J., Yau, K.W., Quigley, H.A., Zack, D.J., Functional genomic screening identifies dual leucine zipper kinase as a key mediator of retinal ganglion cell death. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 4045–4050.
43. Wilson, A.M., Di Polo, A., Gene therapy for retinal ganglion cell neuroprotection in glaucoma. Gene Ther. 19 (2012), 127–136.
44. Zhang, P., Wen, W., Sun, X., He, S., Selective reduction of fMRI responses to transient achromatic stimuli in the magnocellular layers of the LGN and the superficial layer of the SC of early glaucoma patients. Hum. Brain Mapp. 37 (2016), 558–569.
45. Zhu, H., Crabb, D.P., Ho, T., Garway-Heath, D.F., More accurate modeling of visual field progression in glaucoma: ANSWERS. Invest. Ophthalmol. Vis. Sci. 56 (2015), 6077–6083.
46. Zhu, H., Russell, R.A., Saunders, L.J., Ceccon, S., Garway-Heath, D.F., Crabb, D.P., Detecting changes in retinal function: analysis with non-stationary weibull error regression and spatial enhancement (ANSWERS). PLoS One, 9, 2014, e85654.